X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Overall Access To Pharma Info Made Easy With Digital & Paper

Content Team by Content Team
5th October 2023
in IPR Data Management, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The proposal by the European Commission to re-examine the pharmaceutical legislation has ignited an extensive debate. The suggestion in the directive to offer Member States the option to choose among electronic as well as traditional paper medical leaflets builds upon valid worries when it comes to potentially eliminating older and more vulnerable demographics.

MLPS, the Medical Leaflet for Patient Safety, happens to be a subgroup of ECMA, which is the European Carton Makers Association. MLPS happens to be representing the printers of regulated pharmaceutical data, including the likes of package inserts, medication guides, and patient package inserts.

As MLPS, which is a branch of the European Carton Manufacturers Association, these concerns have been shared as they support a complementary approach that effectively has in itself the benefits of both electronic and paper mediums.

Recent surveys have shed light on the significance of this complementarity. According to a study conducted by the European Consumer Organisation, it has been revealed that across Belgium, Italy, Portugal, and Spain, a significant majority of consumers, specifically 79%, express the belief that paper leaflets must be provided alongside medications, even when a QR code option is available. The primary worries happen to be the potential displacing of the elderly, which is cause for worry for 81% of people, and an excessive dependency on the internet, which happens to be a concern for 70% of people.

Although electronic leaflets happen to have many advantages, completely replacing paper leaflets could inadvertently deny many Europeans access to medical data that’s crucial. This action presents a potential risk of medication mistakes and undermines the well-being when it comes to the patients. The existence of the digital divide is indeed supported by Eurostat data, which reveals that only 57% of individuals aged 55–74 regularly make use of the internet. Even in technologically advanced nations such as Denmark, a notable 23% of the population does not have smartphones. In addition to that, digital access continues to be out of reach for a significant number of people, especially in countries where poverty rates are high.

The proposed policy of Print on Demand, which would help the chemists’ print leaflets if asked for, presents numerous challenges. Apart from the increased workload for chemists, there is a clear and concerning challenge of making errors when using standard printers, which could potentially jeopardise patient safety.

Smaller nations that have unique languages encounter a unique set of challenges. That said, eliminating paper leaflets is no way out. The way forward is to embrace a dual approach that includes offering digital translations as well as paper leaflets for those who are less in sync with technology. The printing industry has an excellent opportunity to provide customised solutions for these countries.

Electronic leaflets also happen to raise worries that are related to data privacy. The increasing number of cyber threats has started to question the security of online health data. Ensuring that the patients’ privacy remains uncompromised, it is indeed pivotal to provide them with an access offline, to the information that is critical. 

The proposed shift to electronic leaflets within a five-year timeframe appears to be planned in a hasty way. Taking into account the umpteen digital challenges that many Europeans come across, it would be indeed apt to have a longer ten-year transition window. This will obviously make sure that patient safety is not compromised.

It is well to be noted that moving forward requires an effortless integration of digital as well as traditional elements. By combining the advantages of electronic as well as paper leaflets, one can ensure that every patient has access to safe, comfortable, and secure information. Now is the right time to focus on the well-being of patients and create a revision of pharmaceutical legislation that makes sure that no one gets stranded and left behind.

Previous Post

Importance Of Supply Chain Traceability In The Pharma Sector

Next Post

More Than 600 Medicines At Risk If European PFAS Restriction

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

More Than 600 Medicines At Risk If European PFAS Restriction

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In